Tezepelumab Reduces Patient-reported Cough and Phlegm Production in Patients With Severe, Uncontrolled Asthma: Results From the Phase 3 NAVIGATOR Study

被引：0

作者：

Castro, M. ^{[1
]}

Kraft, M. ^{[2
]}

Ambrose, C. S. ^{[3
]}

Martin, N. ^{[4
,5
]}

Clarke, N. ^{[6
]}

Spahn, J. D. ^{[7
]}

Llanos, J. ^{[8
]}

Ponnarambil, S. ^{[9
]}

机构：

[1] Univ Kansas, Div Pulm Crit Care & Sleep Med, Kansas City, KS USA

[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA

[3] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[4] AstraZeneca, BioPharmaceut R&D, Biometr Late Stage Dev Resp & Immunol, Waltham, MA USA

[5] Cytel, Waltham, MA USA

[6] AstraZeneca, Patient Ctr Sci Resp & Immunol, Gaithersburg, MD USA

[7] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Wilmington, DE USA

[8] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[9] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Cambridge, England

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A4752

引用

页数：2

共 50 条

[41] Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study
Corren, J.
Karpefors, M.
Hellqvist, A.
Parnes, J. R.
Colice, G.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[42] Seasonal variability of exacerbations in patients with severe, uncontrolled asthma and clinical benefits of tezepelumab: Results from the PATHWAY phase 2b study
Corren, J.
Karpefors, M.
Hellqvist, A.
Parnes, J. R.
[J]. ALLERGY, 2020, 75 : 17 - 18
[43] PATIENT-REPORTED TRIGGER NUMBER IS A STRONG PREDICTOR OF UNCONTROLLED DISEASE AMONG PATIENTS WITH SEVERE ASTHMA
Chipps, B.
Soong, W.
Panettieri, R.
Carr, W.
Gandhi, H.
Zhou, W.
Llanos-Ackert, J.
Ambrose, C.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S46 - S47
[44] EFFECT OF TEZEPELUMAB ON A COMPOSITE OF SEVERE ASTHMA EXACERBATIONS AND ACUTE WORSENING EVENTS, COMPEX, IN THE PHASE 3 NAVIGATOR STUDY
Brusselle, G.
Martin, N.
Ponnarambil, S.
Hunter, G.
Hellqvist, A.
Faueras, M.
Da Silva, C. A.
[J]. THORAX, 2022, 77 : A33 - A33
[45] Effect of tezepelumab on a composite of severe asthma exacerbations and acute worsening events, CompEx, in the phase 3 NAVIGATOR study
Brusselle, G.
Martin, N.
Ponnarambil, S.
Hunter, G.
Hellqvist, A.
Fageras, M.
Da Silva, C. A.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
[46] One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study
Shinkai, Masaharu
Ebisawa, Motohiro
Fukushima, Yasushi
Takeuchi, Satomi
Okada, Hiroshi
Tokiyo, Tatsuro
Hayashi, Nobuya
Takikawa, Mami
Colice, Gene
Almqvist, Gun
[J]. JOURNAL OF ASTHMA, 2023, 60 (03) : 616 - 624
[47] Improvement In Patient-Reported Activity Impairment, Stress, And Tiredness In Patients With Severe, Uncontrolled Asthma With Eosinophilic Inflammation: Pooled Results From Two Phase Iii Trials Of Benralizumab
O'Quinn, S.
Xu, X.
Hirsch, I.
Gopalan, G.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
[48] PATIENT-REPORTED ACTIVITY IMPAIRMENT, STRESS, AND TIREDNESS IMPROVEMENT IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH EOSINOPHILIC INFLAMMATION: POOLED RESULTS FROM TWO PHASE III TRIALS OF BENRALIZUMAB
Gopalan, Gokul
O'Quinn, Sean
Xu, Xiao
Hirsch, Ian
[J]. RESPIROLOGY, 2017, 22 : 8 - 9
[49] Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
O'Quinn, Sean
Xu, Xiao
Hirsch, Ian
[J]. JOURNAL OF ASTHMA AND ALLERGY, 2019, 12 : 21 - 33
[50] Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma
Chipps, Bradley E.
Soong, Weily
Panettieri Jr, Reynold A.
Carr, Warner
Gandhi, Hitesh
Zhou, Wenjiong
Cook, Bill
Llanos, Jean-Pierre
Ambrose, Christopher S.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 130 (06) : 784 - 790.e5

← 1 2 3 4 5 →